CALGB 8642 randomizes previously untreated metastatic breast cancer patients either to one of several Phase II agents given for up to four cycles and then followed by standard cyclophosphamide-doxorubicin-5-fluorouracil , or to immediate treatment with standard cyclophosphamide-doxorubicin-5-fluorouracil .
cyclophosphamide-doxorubicin-5-fluorouracil